DAPA-CKD trial for Farxiga is stopped early in patients with chronic kidney disease due to overwhelming efficacy.- AstraZeneca
Related news and insights
Data from prespecified subgroup analyses from FIDELITY, a prespecified pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD trials, indicate that compared to placebo, finerenone consistently reduced the risk of the composite CV and kidney outcomes compared with placebo in addition to standard of care in patients across a broad spectrum of CKD associated with T2D, irrespective of a prior history of ASCVD ( atherosclerotic CV disease ).
Lexicon Pharmaceuticals announced results of a new analysis of data from the SCORED Phase III clinical trial of Zynquista (sotagliflozin) in patients with type 2 diabetes and chronic kidney disease. The SCORED clinical trial randomized 10,584 patients with type 2 diabetes and chronic kidney disease to sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, or placebo.
Bayer announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has granted marketing authorization for finerenone under the brand name Kerendia.